Management. Founders.
Michael E. Pape, PhD MBA - CEO/CSO, co-founder
Dr. Pape designs, develops, and manages the internal and external drug discovery programs; he sets scientific priorities and oversees the scientific team.
Dr. Pape is a founding partner of Sigvion Capital, a venture capital firm. He is a co-founder of Esperion Therapeutics (sold to Pfizer in 2004 for $1.3 billion) and Akebia Therapeutics. He worked as a scientist at Upjohn, Parke-Davis, and Pfizer directing drug discovery and publishing extensively on metabolic diseases.
Pape received his Ph.D. in Biochemistry from Purdue University, his MBA from the University of Chicago Graduate School of Business, and his bachelor's degree in Microbiology from the University of Michigan.
J. P. Fairbank - President, co-founder
Mr. Fairbank manages operations, finance, and business development (partnerships, licensing, fundraising.) He directs the computational aspects of the company's technology and platorm. He is the Chairman of the Board.
Fairbank is a founding partner of Sigvion Capital, a venture capital firm founded in 2004, and a co-founder of Akebia Therapeutics. Before escaping to VC/entrepreneurship he survived a decade in investment banking and investment management.
Fairbank received his MBA from the University of Chicago Graduate School of Business (Booth) and his bachelor's degree in Economics from Connecticut College.
Hashim al-Hashimi - Inventor, Platform Architect, co-founder
Prof. Al-Hashimi is the inventor of the technology underlying Nymirum's platform. He provides specific direction on the particulars of each unique RNA target.
Al-Hashimi is the Robert L. Kuczkowski Professor of Chemistry and Professor of Biophysics at the University of Michigan. He received his PhD from Yale University, worked as a Research Scientist at Sloan-Kettering, and is the recepient of the National Science Foundation Career Award. His breakthroughs in RNA research have been repeatedly published in Science and Nature.